What does Epana Bio do?

Epana Bio is a stealth-stage biotech developing precision therapies that target the cellular origin of autoimmune disease.

Who are Epana Bio's investors?

Epana Bio's investors include Breakout Labs, Breakout Ventures, HAWKTAIL, Hummingbird Ventures, OMX Ventures, KdT Ventures, Refactor Capital.

Epana Bio

7 known investors

Epana Bio develops therapies for autoimmune diseases by leveraging genomics and AI to identify and target cellular origins of disease, with a focus on precision medicine for patient populations.

Also known as Epana

AI & Machine Learning Biotech Digital Health

Investors · 7

Breakout Labs

Breakout VenturesSan Francisco · $500K – $6M

HAWKTAILSan Francisco

Hummingbird VenturesSingapore · $500K – $10M

OMX VenturesLincolnshire

KdT VenturesreportedAustin · $500K – $3M

Refactor CapitalreportedBurlingame · $1M – $2M

Company profile

researched Aug 2026

Epana Bio is a biotechnology company developing precision therapies for autoimmune disease. Its stated approach is to treat autoimmunity by targeting the cellular origin of disease rather than managing symptoms, with the goal of resetting the immune system. The company uses genomics and artificial intelligence to design treatments tailored to individual patients and to accelerate drug discovery.

The company operates in stealth mode and is headquartered in Berkeley, California, with an address on College Avenue; it is also associated with San Francisco through the South Park Commons community. It was founded by Danny Wells, described as an immunologist and data scientist. Its website articulates operating principles including a belief that small, focused teams can compete through nimbleness and pace of execution, and it advertises open positions and a general contact address.

Founding story

Epana Bio was founded by Danny Wells, an immunologist and data scientist, and appears in the South Park Commons company directory with a 2025 designation.

Traction

The company remains in stealth mode with no publicly disclosed products or clinical programs; it lists open positions on its website, though a South Park Commons listing shows no open roles.

▸Full profile — market position, technology, go-to-market, geography

Market position

Epana Bio is an early, seed-stage, stealth-mode biotechnology company positioned in precision medicine and AI-enabled drug discovery for autoimmune disease. Company-comparison listings group it with other biotechnology and drug-discovery companies such as Dren Bio, UCB and Cullinan Oncology.

Technology

Epana Bio applies genomics and artificial intelligence to identify and target the cellular origin of autoimmune disease and to design therapies tailored to individual patients. Descriptions of the company associate it with drug discovery approaches including targeted cell depletion, T-cell engagers (TCEs) and bispecific antibodies, and with in silico drug discovery.

Go-to-market

The company's stated focus is patients with autoimmune disease, for whom it aims to develop therapies designed specifically for them.

Geography

Headquartered in Berkeley, California (3036 College Avenue, Berkeley, CA 94705), with a San Francisco association through South Park Commons.

Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported

Funding stageJan 2025Seed

Operating statusJan 2025Stealth mode

Year foundedJan 20242024

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

Competitors · 3

by search overlap

Day One Biopharmaceuticals7 shared keywordsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

AnaptysBio3 shared keywordsAnaptysBio manages the financial collaborations from Jemperli (with GSK) and imsidolimab (with Vanda), operating a virtual model focused on protecting and returning royalty and milestone value to stockholders. It is a publicly traded biotech company running with fewer than ~10 contractors.

Arvinas Holding Co. LLC3 shared keywordsArvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology. It advances preclinical research into clinical-stage treatments for patients with limited or ineffective existing options.

Companies competing with Epana Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

▸Research sources · 7

primary sources listed

Epana Bioepana.bio · web

7 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Epana Bio do?: Epana Bio is a stealth-stage biotech developing precision therapies that target the cellular origin of autoimmune disease.
Who are Epana Bio's investors?: Epana Bio's investors include Breakout Labs, Breakout Ventures, HAWKTAIL, Hummingbird Ventures, OMX Ventures, KdT Ventures, Refactor Capital.